Table 1 Comparisons of demographic and clinical features of patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who received initial teicoplanin treatment (n = 28) and those who received ß-lactam antibiotic treatment (n = 56)
Variables | All population | Propensity-matching group | ||||
|---|---|---|---|---|---|---|
Initial teicoplanin treatment n = 28 | Initial ß-lactam treatment n = 56 | P | Initial teicoplanin treatment n = 28 | Initial ß-lactam treatment n = 28 | P* | |
Demographics | ||||||
Male gender, n (%) | 17 (60.7) | 37 (66.1) | 0.64 | 17 (60.7) | 17 (60.7) | > 0.99 |
Age, mean (IQR), years | 75 (62–81) | 67 (55–76) | 0.06 | 75 (62–81) | 75 (65–84) | NA |
Length of hospital stay, mean (range), days | 26 (15–30) | 21 (12–31) | 0.29 | 26 (15–30) | 16 (9–33) | 0.31 |
MIC of teicoplanin ≥ 1.5 mg/L, n (%) | 6 (21.4) | 23 (41.1) | 0.09 | 6 (21.4) | 9 (32.1) | 0.33 |
Comorbidities, n (%) | ||||||
Coronary artery disease | 12 (42.9) | 5 (8.9) | < 0.01 | 12 (42.9) | 3 (10.7) | 0.03 |
Diabetes mellitus | 12 (42.9) | 22 (39.3) | 0.82 | 12 (42.9) | 8 (28.6) | 0.26 |
Hypertension | 18 (64.3) | 25 (44.6) | 0.11 | 18 (64.3) | 11 (39.3) | 0.08 |
Solid tumor | 10 (35.7) | 9 (16.1) | 0.06 | 10 (35.7) | 4 (14.3) | 0.08 |
Hematology malignancy | 0 | 1 (1.8) | > 0.99 | 0 | 1 (3.6) | 0.61 |
Liver cirrhosis | 1 (3.6) | 6 (10.7) | 0.42 | 1 (3.6) | 3 (10.7) | 0.34 |
Chronic obstructive pulmonary disease | 3 (10.7) | 4 (7.1) | 0.68 | 3 (10.7) | 2 (71.4) | 0.66 |
IV drug abuser | 0 | 4 (7.1) | 0.30 | 0 | 2 (71.4) | 0.47 |
Congestive heart failure | 11 (39.3) | 4 (7.1) | < 0.01 | 11 (39.3) | 3 (10.7) | 0.04 |
End-stage renal disease | 7 (25.0) | 13 (23.2) | > 0.99 | 7 (25.0) | 7 (25.0) | > 0.99 |
Cerebral vascular accident | 7 (25.0) | 16 (28.6) | 0.80 | 7 (25.0) | 8 (28.6) | 0.76 |
Prosthetic device implantation | 15 (53.6) | 17 (30.4) | 0.06 | 15 (53.6) | 7 (25.0) | 0.05 |
Pittsburgh bacteremia score ≥ 4a | 14 (50.0) | 16 (28.6) | 0.09 | 14 (50.0) | 14 (50.0) | NA |
Source of bacteremiab, n (%) | ||||||
Catheter-related bacteremia | 10 (35.7) | 7 (12.5) | 0.02 | 10 (35.7) | 4 (14.3) | 0.10 |
Bone and joint infection | 5 (17.9) | 16 (28.6) | 0.42 | 5 (17.9) | 6 (21.4) | 0.74 |
Infective endocarditis | 0 | 6 (10.7) | 0.17 | 0 | 4 (14.3) | 0.31 |
Skin and soft infection | 4 (14.3) | 13 (23.2) | 0.40 | 4 (14.3) | 6 (21.4) | 0.53 |
Intra-abdominal infection | 0 | 1 (1.8) | > 0.99 | 0 | 1 (3.6) | 0.61 |
Urinary tract infection | 0 | 1 (1.8) | > 0.99 | 0 | 1 (3.6) | 0.61 |
Pneumonia | 3 (10.7) | 5 (8.9) | > 0.99 | 3 (10.7) | 2 (28.6) | 0.57 |
Primary bacteremia | 4 (14.3) | 5 (8.9) | 0.47 | 4 (14.3) | 2 (28.6) | 0.18 |
Adequate infection source control ratee n/N | 15/19 (78.9) | 15/36 (41.7) | 0.01 | 15/19 (78.9) | 14/16 (87.5) | 0.67 |
Clinical outcome, n (%) | ||||||
Short-term favorable outcomec | 11 (39.3) | 34 (60.7) | 0.10 | 11 (39.3) | 11 (39.3) | > 0.99 |
Favorable outcomed | 24 (85.7) | 43 (76.8) | 0.40 | 24 (85.7) | 18 (64.3) | 0.07 |
Persistent bacteremiaf n/N | 5/24 (20.8) | 11/30 (36.7) | 0.24 | 5/24 (20.8) | 6/16 (37.5) | 0.30 |
30-day overall mortality | 4 (14.3) | 13 (23.2) | 0.40 | 4 (14.3) | 10 (35.7) | 0.07 |